| This week's sponsor is Deloitte. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, July 16, 2018 Recalls of certain drugs containing heart drug valsartan supplied by Zhejiang Huahai Pharmaceutical have spread to the U.S., as the FDA announced voluntary actions to take some affected drugs off the shelves due to potential cancer risk. |
|
|
| This week's sponsor is Biotech Primer. | |  | |
Top Stories Of The Week Wednesday, July 18, 2018 Novartis, whose personalized CAR-T cancer treatment Kymriah won an approval in May to treat relapsed large B-cell lymphoma, said Wednesday it has run into some manufacturing issues around that condition. Monday, July 16, 2018 It’s an interesting trip, reading the comprehensive account of Theranos’ rise and fall, and that of its founder, Elizabeth Holmes—especially when taken as a careful watcher of the biotech industry or simply knowing the tale’s ending, such as it is. Tuesday, July 17, 2018 Jennifer Petter, Arrakis’ chief scientific officer, and Clark Musto, a clinical research manager at Johnson & Johnson's Janssen unit, both transitioned this year and shared what it means to be trans in the biotech industry. Tuesday, July 17, 2018 Pfizer is taking heat from Congress and Wall Street analysts alike—not for bowing to President Donald Trump's pressure to hold off on price increases, but for the tepid nature of its promises. Wednesday, July 18, 2018 Pfizer and Eli Lilly’s nerve growth factor (NGF) inhibitor tanezumab has inched closer to becoming the first alternative to opioid analgesics for severe pain after hitting the mark in a phase 3 trial. Monday, July 16, 2018 PARP inhibitors have revolutionized the treatment of ovarian cancer with BRCA mutations and are starting to take off in breast cancer treatment, too. But the way that these drugs work could make them applicable to many more cancer types, some oncology researchers believe. Monday, July 16, 2018 Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread. But it’ll be a mano a mano with Johnson & Johnson, whose rival drug Erleada has a four-month head start thanks to an earlier-than-expected FDA approval. Tuesday, July 17, 2018 U.K.-based CRO Clinigen has bought the rights to Novartis’ Proleukin (aldesleukin) outside the U.S. as it looks to boost sales with new dosing and tie-ups with other drugs. Tuesday, July 17, 2018 China’s drug regulator just pulled a manufacturing permit for the country’s second-largest maker of rabies vaccines over data falsification, marking the latest episode in China’s drug safety scandal. Resources Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
